A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
Earnings and shelf registration put Bicara Therapeutics (BCAX) in focus Bicara Therapeutics (BCAX) is drawing attention after reporting a fourth quarter net loss of US$37.39 million and a full year 2025 net loss of US$137.95 million, alongside a new US$70.36 million shelf registration. See our latest analysis for Bicara Therapeutics. At a share price of US$20.85, Bicara's recent quarterly loss update and the US$70.36 million shelf registration have come alongside a 90 day share price return of 28.78% and a one year total shareholder return of 119.24%. This suggests momentum has been building even as risks remain front of mind for investors. If this kind of earnings driven move has you scanning for other ideas in healthcare, it could be a good moment to check out 37 healthcare AI stocks With the share price up strongly over the past year and analysts publishing a higher price target than today's US$20.85 level, the real question is whether Bicara is still mispriced or if mar
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]Seeking Alpha
- Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.MarketBeat
BCAX
Earnings
- 3/30/26 - Beat
BCAX
Sec Filings
- 3/31/26 - Form S-8
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- BCAX's page on the SEC website